Physician profile
Richa Dawar
NPI 1760777361
$53,942.66
in general payments reported to CMS, 2019-2025
35 companies · $4,453 in 2025
The $4,453 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $9,156 · 2021: $5,415 · 2022: $1,628 · 2023: $10K · 2024: $22K · 2025: $4,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Honoraria: $8,400 · Food and Beverage: $4,086 · Travel and Lodging: $3,757 · Long Term Medical Supply Or Device Loan: $299 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,970.18 |
| Honoraria | $8,400.00 |
| Food and Beverage | $4,085.67 |
| Travel and Lodging | $3,757.19 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $32,027.45 | 2022-2025 | Optune Lua (Novottf-200t) |
| Daiichi Sankyo INC. | $7,093.13 | 2020-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals Lp | $6,907.62 | 2019-2025 | Tagrisso, Enhertu |
| Novartis Pharmaceuticals Corporation | $2,633.13 | 2020-2025 | Kisqali |
| G1 Therapeutics, INC. | $1,500.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $950.00 | 2019 | |
| Emd Serono, INC. | $500.00 | 2021 | |
| Tersera Therapeutics LLC | $354.00 | 2025 | Zoladex |
| Pfizer INC. | $351.74 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $228.32 | 2023-2025 | Lynparza, Keytruda, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $189.36 | 2019-2025 | Opdivo |
| Caris Mpi, INC. | $132.27 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $127.63 | 2021-2025 | Trodelvy |
| Array Biopharma INC | $120.10 | 2023-2025 | Lorbrena, Braftovi, Mektovi |
| Amgen INC. | $101.60 | 2019-2023 | Lumakras |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $96.11 | 2021-2025 | Rybrevant |
| Seagen INC. | $95.00 | 2025 | |
| Lilly USA, LLC | $62.91 | 2020-2024 | Verzenio, Jaypirca |
| Sun Pharmaceutical Industries INC. | $61.54 | 2024-2025 | |
| Ge Healthcare | $52.86 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.26 | 2023 | Alunbrig |
| Exelixis INC. | $42.53 | 2025 | Cabometyx |
| Tempus Ai, INC | $40.42 | 2024 | Xt Cdx |
| Genentech USA, INC. | $29.51 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $25.68 | 2024 | Clonoseq |
| Servier Pharmaceuticals LLC | $24.94 | 2025 | |
| Glaxosmithkline, LLC. | $22.07 | 2024 | Zejula, Jemperli |
| Ipsen Biopharmaceuticals, INC | $21.52 | 2024 | Somatuline Depot, Onivyde |
| Foundation Medicine, INC. | $19.60 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.49 | 2024 | Ultomiris |
| Mirati Therapeutics, INC. | $18.97 | 2024 | Krazati |
| Taiho Oncology, INC. | $17.76 | 2025 | |
| Astellas Pharma US INC | $14.64 | 2022 | |
| Coherus Oncology, INC. | $13.50 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richa Dawar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.